It is generally believed that this type of tumor does not respond to anti-PD-1/PD-L1 therapy, while antagonizing the TGF-β signaling pathway significantly improves anti-PD-1/PD-L1 therapeutic resistance and enhances the effect of antitumor immunotherapy (53, 127). This evidence concerns the gene PDCD1 and neoplasm.